Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4405 ARTÍCULOS , VIENDO DEL 3961 AL 3975

Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story

Vermeiren Y, De Deyn PP.

Neurochem Int. 2017 Jan;102:22-32. doi: 10.1016/j.neuint.2016.11.009. Epub 2016 Nov 27.

Cognitive Training in Parkinson's Disease

Walton CC, Naismith SL, Lampit A, Mowszowski L, Lewis SJ.

Neurorehabil Neural Repair. 2017 Mar;31(3):207-216. doi: 10.1177/1545968316680489. Epub 2016 Dec 13.

Central hemodynamics and arterial stiffness in idiopathic and multiple system atrophy

Franzen K, Fliegen S, Koester J, Martin RC, Deuschl G, Reppel M, Mortensen K, Schneider SA.

J Neurol. 2017 Feb;264(2):327-332. doi: 10.1007/s00415-016-8352-4. Epub 2016 Nov 29.

Orthostatic hypotension, cognition, and Parkinson disease: Dumbing down by standing up

Boylan LS, Messinis L.

Neurology. 2017 Jan 3;88(1):11-12. doi: 10.1212/WNL.0000000000003468. Epub 2016 Nov 30.

MAPT mutation associated with frontotemporal dementia and parkinsonism (FTDP-17)

Haussmann R, Wysocki M, Brandt MD, Hermann A, Donix M.

Int Psychogeriatr. 2017 May;29(5):869-871. doi: 10.1017/S1041610216002192. Epub 2016 Dec 1.

What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders

Martinez-Martin P.

Mov Disord. 2017 Mar;32(3):382-392. doi: 10.1002/mds.26885. Epub 2016 Dec 2.

Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation

Pal GD, Ouyang B, Serrano G, Shill HA, Goetz C, Stebbins G, Metman LV, Driver-Dunckley E, Mehta SH, Caviness JN, Sabbagh MN, Adler CH, Beach TG; Arizona Study of Aging Neurodegenerative Disorders.

Mov Disord. 2017 Feb;32(2):274-277. doi: 10.1002/mds.26882. Epub 2016 Dec 2.

Association between Parkinson's disease and risk of colorectal cancer

Xie X, Luo X, Xie M.

Parkinsonism Relat Disord. 2017 Feb;35:42-47. doi: 10.1016/j.parkreldis.2016.11.011. Epub 2016 Nov 22.

A revisit to quantitative PET with (18)F-FDOPA of high specific activity using a high-resolution condition in view of application to regenerative therapy

Akamatsu G, Ohnishi A, Aita K, Nishida H, Ikari Y, Sasaki M, Kohara N, Senda M.

Ann Nucl Med. 2017 Feb;31(2):163-171. doi: 10.1007/s12149-016-1143-2. Epub 2016 Dec 2.

Is there a role for ghrelin in central dopaminergic systems? Focus on nigrostriatal and mesocorticolimbic pathways

Stievenard A, Méquinion M, Andrews ZB, Destée A, Chartier-Harlin MC, Viltart O, Vanbesien-Mailliot CC.

Neurosci Biobehav Rev. 2017 Feb;73:255-275. doi: 10.1016/j.neubiorev.2016.11.021. Epub 2016 Nov 30.

Subthalamic nucleus stimulation and gait in Parkinson's Disease: a not always fruitful relationship

Cossu G, Pau M.

Gait Posture. 2017 Feb;52:205-210. doi: 10.1016/j.gaitpost.2016.11.039. Epub 2016 Nov 27.

Gaucher disease: Progress and ongoing challenges

Mistry PK, Lopez G, Schiffmann R, Barton NW, Weinreb NJ, Sidransky E.

Mol Genet Metab. 2017 Jan-Feb;120(1-2):8-21. doi: 10.1016/j.ymgme.2016.11.006. Epub 2016 Nov 17.

Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders

Hasegawa M, Nonaka T, Masuda-Suzukake M.

Pharmacol Ther. 2017 Apr;172:22-33. doi: 10.1016/j.pharmthera.2016.11.010. Epub 2016 Dec 1.

Aberrant regional homogeneity in Parkinson's disease: A voxel-wise meta-analysis of resting-state functional magnetic resonance imaging studies

Pan P, Zhan H, Xia M, Zhang Y, Guan D, Xu Y.

Neurosci Biobehav Rev. 2017 Jan;72:223-231. doi: 10.1016/j.neubiorev.2016.11.018. Epub 2016 Dec 1.

Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease

Valdés EG, O'Connor ML, Uc EY, Hauser RA, Andel R, Edwards JD.

Int J Neurosci. 2017 Oct;127(10):841-848. doi: 10.1080/00207454.2016.1269088. Epub 2016 Dec 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias